Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
ANTICIPATE trial: what clinicians have said so far
A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer
- NCT04813107 ↗
- Unknown
- Jiangsu Yahong Meditech Co., Ltd aka Asieris
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on ANTICIPATE yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ANTICIPATE so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 5 posts on X, typically up to 22 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase I/II Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer (MIBC)
- Phase
- Phase 1/Phase 2
- Status
- Unknown
- Conditions
- Muscle Invasive Bladder Cancer
- Interventions
- APL-1202 in combination with tislelizumab; Tislelizumab alone
- Arms
- APL-1202 in combination with tislelizumab · Active comparator
- Tislelizumab alone · Placebo comparator
- Enrollment
- 79 (estimated)
- Primary outcomes
- Adverse events (AE) and serious adverse events (SAE).
- The RP2D of APL-1202 in combination with tislelizumab.
- The rate of pathologic complete response (pCR) in Phase 2.
- Sponsor
- Jiangsu Yahong Meditech Co., Ltd aka Asieris
- Start
- Dec 28, 2021
- Primary completion
- Nov 1, 2023 (estimated)
- Results posted
- No
- Registry record
- NCT04813107 · updated Feb 22, 2022